Acelrx announces agreement with fda addressing the warning letter received for dsuvia® promotional materials

Hayward, calif., june 17, 2021 /prnewswire/ -- acelrx pharmaceuticals, inc. (nasdaq: acrx), (acelrx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced it has reached agreement with the food and drug administration (fda) with regards to finalizing corrective actions acelrx has taken or plans to take in response to the previously announced fda warning letter, dated february 11, 2021, regarding certain dsuvia promotional materials.
ACRX Ratings Summary
ACRX Quant Ranking